Document is current

Any future updates will be listed below

The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations

Crossref DOI link: https://doi.org/10.1186/s40360-017-0190-1

Published Online: 2017-12-13

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark